Winnipeg, June 4, 2024. - TheNewswire - Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, is pleased to announce that its CEO Dr. Steven Theriault, is set to present at TEDx Winnipeg on June 6, 2024, at the Prairie Theatre Exchange. Dr. Theriault’s topic, highly relevant to today’s antibiotic resistant world, is ‘Bacteriophages as the silent cure to antimicrobial resistance’ (AMR).

 

Click Image To View Full Size

TEDx events offer an intriguing mix of scientists, entrepreneurs and artists that have one thing in common -  they bring forward disruptive ideas in their respective sectors, challenging established concepts and encouraging new perspectives and thinking. Dr. Theriault, who has a PhD in molecular genetics and virology and 15 years experience at Canada’s National Microbiology Lab, is a uniquely qualified presenter. He is at the forefront of the global battle against antibiotic resistant “superbugs”. His company, Cytophage, and its team of scientists, develop highly specific bacteriophages, viruses that destroy harmful bacteria.  

With more attention on the threat of AMR in the media, and the World Health Organization identifying AMR as one of the top global public health and development threats1, the search for viable solutions is an opportune topic for a TED event.  

 

“The worldwide overuse of antibiotics and increased globalization has created the next human health catastrophe in which resistant bacteria are spreading faster than at any other time in history”, commented CEO Dr. Steven Theriault. “Cytophage is truly meeting the moment by developing phages that can uniquely combat bacteria strains that have become resistant to antibiotics. I am thrilled to discuss our innovative phage technology and its potential applications with an ever-growing TEDx audience.”

 

TEDx is the grassroots TED initiative with the mission to discover “ideas worth spreading,” with talks from local speakers who share ideas that help people understand and navigate the world. Volunteers from the local community organize a TEDx event, and just like TED events, its goal is to spark conversation, connection, and community. All TEDx Winnipeg speakers and organizers are volunteers who are committed to developing and building innovative ideas. More information about the TEDx Winnipeg event is available at https://tedxwinnipeg.ca/.

  

For further information please contact:

 

Heather Medwick

Chief Operating Officer

heather@cytophage.com

431 388 8873

Cytophage Investor Alerts: https://cytophage.com/subscribe/

 

About Cytophage Technologies

 

Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.

 

Cautionary Statement on Forward-Looking Information

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are

described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

 

1 https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance